Cardiology, Bern University Hospital, Bern, Switzerland.
Catheter Cardiovasc Interv. 2011 Aug 1;78(2):304-13. doi: 10.1002/ccd.22948. Epub 2011 Jul 15.
Temporary percutaneous left ventricular assist devices (TPLVAD) can be inserted and removed in awake patients. They substitute left ventricular function for a period of up to a few weeks and provide an excellent backup and bridge to recovery or decision.
Retrospective analysis of 75 patients who received TPLVAD to treat cardiogenic shock (n = 49) or to facilitate high-risk percutaneous coronary intervention (PCI) (n = 26). Forty-two patients with cardiogenic shock and 16 patients with high-risk PCI received a TandemHeart and 7 patients and 10 patients, respectively, received an Impella Recover LP 2.5. Outcome and related complications up to 1 month are reported with reference to device depending function.
One-month survival was 53% in patients with shock and 96% in patients with PCI.
TPLVADs can support the failing heart with acceptable risk. Outcome is better in prophylactic use than in patients with cardiogenic shock.
临时经皮左心室辅助装置（TPLVAD）可在清醒患者中插入和移除。它们可以替代左心室功能长达数周，并为恢复或决策提供出色的后备和桥接。
回顾性分析了 75 例接受 TPLVAD 治疗心源性休克（n = 49）或促进高危经皮冠状动脉介入治疗（PCI）（n = 26）的患者。42 例心源性休克患者和 16 例高危 PCI 患者接受了 TandemHeart，7 例和 10 例患者分别接受了 Impella Recover LP 2.5。根据设备相关功能报告了 1 个月内的预后和相关并发症。
休克患者的 1 个月生存率为 53%，PCI 患者的 1 个月生存率为 96%。
TPLVAD 可以以可接受的风险支持衰竭的心脏。预防性使用的结果优于心源性休克患者。
